OraSure Technologies Appoints Steven K. Boyd to its Board of Directors
OraSure Technologies (NASDAQ: OSUR) announced the appointment of Steven K. Boyd to its Board of Directors as a Class II director, effective October 28, 2025. The company also appointed Jack Kenny as Board Chair and said Mara Aspinall will step down after more than eight years of service.
OraSure said the board changes are part of ongoing refreshment: the board now has seven directors, six independent, and three new independent directors added in the past three years. The release highlights strengthened balance sheet, improved profitability and cash flow, returned capital to shareholders, and a focus on diagnostics and sample management growth.
OraSure Technologies (NASDAQ: OSUR) ha annunciato la nomina di Steven K. Boyd nel Consiglio di Amministrazione come membro di Classe II, con effetto dal 28 ottobre 2025. L'azienda ha anche nominato Jack Kenny come Presidente del Consiglio e ha dichiarato che Mara Aspinall farà un passo indietro dopo oltre otto anni di servizio.
OraSure ha dichiarato che i cambiamenti nel consiglio fanno parte di un rinnovamento in corso: il consiglio ora è composto da sette membri, sei indipendenti, e tre nuovi indipendenti aggiunti negli ultimi tre anni. Il comunicato sottolinea una maggiore solidità patrimoniale, una redditività e un flusso di cassa migliori, la restituzione di capitale agli azionisti e un focus sulla crescita di diagnostica e gestione dei campioni.
OraSure Technologies (NASDAQ: OSUR) anunció la designación de Steven K. Boyd a su Junta Directiva como director de Clase II, con efecto a partir del 28 de octubre de 2025. La empresa también designó a Jack Kenny como Presidente de la Junta y señaló que Mara Aspinall dejará el cargo tras más de ocho años de servicio.
OraSure indicó que los cambios en la Junta forman parte de una renovación continua: la Junta ahora cuenta con siete directores, seis independientes, y se añadieron tres nuevos directores independientes en los últimos tres años. El comunicado destaca un fortalecimiento del balance, una mayor rentabilidad y flujo de caja, la devolución de capital a los accionistas y un enfoque en el crecimiento de diagnóstico y gestión de muestras.
OraSure Technologies (NASDAQ: OSUR)가 2025년 10월 28일부로 이사회의 클래스 II 이사로 Steven K. Boyd를 임명했다고 발표했습니다. 또한 Jack Kenny를 이사회 의장으로 임명했고 Mara Aspinall가 8년이 넘는 기간의 근무를 마치고 물러날 것이라고 밝혔습니다.
OraSure는 이사회 변화가 지속적인 갱신의 일부라고 밝혔습니다: 이사회는 현재 7명의 이사로 구성되며, 그 중 6명은 독립적이고, 지난 3년 동안 3명의 새로운 독립 이사가 추가되었습니다. 발표문은 강화된 재무상태표, 개선된 수익성 및 현금 흐름, 주주에 대한 자본 환원 및 진단 및 샘플 관리 성장에 대한 집중을 강조합니다.
OraSure Technologies (NASDAQ : OSUR) a annoncé la nomination de Steven K. Boyd au conseil d'administration en tant qu'administrateur de classe II, à compter du 28 octobre 2025. L'entreprise a également nommé Jack Kenny président du conseil et a déclaré que Mara Aspinall se retirera après plus de huit années de service.
OraSure a indiqué que les changements au conseil font partie du renouvellement en cours : le conseil compte désormais sept administrateurs, six indépendants, et trois nouveaux administrateurs indépendants ajoutés au cours des trois dernières années. Le communiqué met en avant un bilan renforcé, une rentabilité et des flux de trésorerie améliorés, la restitution de capital aux actionnaires et un accent sur la croissance du diagnostic et de la gestion des échantillons.
OraSure Technologies (NASDAQ: OSUR) gab die Ernennung von Steven K. Boyd in den Verwaltungsrat als Class-II-Direktor bekannt, mit Wirkung ab dem 28. Oktober 2025. Das Unternehmen ernannte auch Jack Kenny zum Vorsitzenden des Vorstands und sagte, Mara Aspinall werde nach mehr als acht Jahren im Amt zurücktreten.
OraSure sagte, die Änderungen im Vorstand seien Teil einer laufenden Erneuerung: Der Vorstand besteht jetzt aus sieben Direktoren, sechs unabhängig, und in den letzten drei Jahren wurden drei neue unabhängige Direktoren hinzugefügt. Die Mitteilung hebt ein gestärktes Bilanzbild, verbesserte Rentabilität und Cashflow, die Rückführung von Kapital an die Aktionäre sowie einen Fokus auf Diagnostik und Probenverwaltung hervor.
أعلنت شركة OraSure Technologies (مدرجة في ناسداك: OSUR) عن تعيين ستيفن ك. بُويد في مجلس الإدارة كعضو من الفئة الثانية، اعتباراً من 28 أكتوبر 2025. كما عينت الشركة جاك كيني رئيساً للمجلس وقالت إن مَرا أسبينال ستتولى التقاعد بعد أكثر من ثمانية أعوام من الخدمة.
وقالت OraSure إن تغييرات المجلس جزء من تحديث مستمر: المجلس الآن يتكوّن من سبعة أعضاء، ستة مستقلين، وأُضيف ثلاثة أعضاء مستقلين جدد في السنوات الثلاث الماضية. تسلط البيان الضوء على تعزّز الميزانية، وتحسن الربحية وتدفق النقد، وإعادة رأس المال إلى المساهمين، والتركيز على نمو التشخيص وإدارة العيّنات.
OraSure Technologies (NASDAQ: OSUR)宣布任命 Steven K. Boyd 为董事会的II类董事，自2025年10月28日生效。公司还任命 Jack Kenny 为董事会主席，并表示 Mara Aspinall 将在超过八年的任职后辞任。
OraSure 表示董事会的变动是持续刷新的一部分：董事会现在共有七名董事，其中六名为独立董事，在过去三年中新增了三名独立董事。公告强调强化的资产负债表、改善的盈利能力和现金流、回馈股东的资本，以及专注于诊断和样本管理增长。
- Steven K. Boyd appointed to Board effective Oct 28, 2025
- Jack Kenny named Chair effective Oct 28, 2025
- Board now 7 directors, 6 independent
- Three independent directors added in the past 3 years
- Company reports strengthened balance sheet and improved profitability
- Long-serving director Mara Aspinall to step down after 8+ years
- Ongoing board turnover: 3 new directors in three years could affect continuity
Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective
OraSure Board Has Added Three New Independent Directors in the Past Three Years
Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board
BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure’s ongoing Board refreshment efforts, which have brought three new independent directors to the Board in the past three years, significantly increasing operational, financial, and industry expertise.
Mr. Boyd’s appointment comes at an exciting time for OraSure as the Company builds on its successful multi-year transformation and continues to drive operational excellence, expand its diagnostics and sample management portfolio, and position the business for sustainable, profitable growth. Over the past several years, OraSure has strengthened its balance sheet, improved profitability and cash flow, returned capital to shareholders, streamlined operations, and reshaped its portfolio to focus on its highest-growth opportunities in diagnostics and sample management solutions.
Mr. Boyd was selected following a comprehensive search process, conducted with the assistance of a leading independent search firm, to complement the Board's existing credentials, experience and qualifications. Mr. Boyd is a seasoned investor, who brings a valuable shareholder perspective and more than two decades of public markets experience across healthcare. He most recently served as Partner at Camber Capital Management, where for over 15 years he helped to grow the firm’s assets under management from around
“We are thrilled that Steve will be joining our Board as we continue to advance our innovation roadmap and expand our commercial reach,” said Carrie Eglinton Manner, President and CEO of OTI. “Steve is a highly accomplished investor and healthcare leader with a track record of identifying value creation opportunities and helping companies deliver growth. He brings the rare combination of deep understanding of investor priorities, sector depth, and strategic judgment that will be highly additive as OraSure pursues its next phase of growth.”
“As a former investor in OraSure, I have closely followed the Company’s transformation and have been impressed by its operational progress, disciplined execution, and clear strategy for profitable growth,” said Mr. Boyd. “I am excited to join the Board and look forward to contributing my perspective as the Company continues to build on its momentum and pursue new opportunities for shareholder value creation.”
Additionally, the Board has appointed Jack Kenny, who has served as a director since September 2024, as its Chair, effective immediately. He succeeds Mara Aspinall, who has decided to step down from the Board after more than eight years of service. Mr. Kenny previously served as CEO of Meridian Bioscience and has more than 30 years of leadership experience in in-vitro diagnostics, molecular, and lab services, along with broad operational and commercial management expertise.
“I’m delighted to be appointed Chair of OraSure’s Board as we continue to take important steps to deliver for our customers and shareholders,” said Mr. Kenny. “We have made significant strides in reshaping OraSure’s portfolio and strengthening its foundation for the future. I look forward to our Board’s continued work to drive profitable growth and shareholder value creation. On behalf of everyone at OraSure, I want to thank Mara for her leadership and dedication, which have helped position OraSure for continued success. We wish her the very best in her future endeavors.”
Ms. Aspinall commented, “It has been a privilege to serve OraSure during a pivotal time for the Company. OraSure is stronger than ever, and with Jack as Chair of the Board, I am confident the Company is well positioned to accelerate its growth trajectory. I look forward to watching its continued success as I take on my next challenge.”
With the changes announced today, the OraSure Board comprises seven directors, six of whom are independent and three of whom have joined in the past three years. Collectively, the directors bring deep operational, financial, M&A, and life sciences expertise, underscoring OraSure’s continued focus on profitable growth, innovation, and value creation for shareholders.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com
Forward-Looking Statements
This press release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations of future events and are not guarantees of future performance or results. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: uncertainty of commercial success; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; uncertainty of regulatory approvals; ability to comply with applicable regulatory requirements; uncertainty relating to patent protection and potential patent infringement claims; impact of competitors, competing products and technology changes and patents obtained by competitors; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; impact of negative economic conditions; changes in behavior and spending patterns of purchasers; trends toward healthcare cost containment; product efficacy or safety concerns resulting in product recalls or regulatory action; and changes to applicable laws and regulations. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure undertakes no duty to update these statements.
| Investor Contact: | Media Contact: |
| Jason Plagman | Amy Koch |
| VP, Investor Relations | Director, Corporate Communications |
| investorinfo@orasure.com | media@orasure.com |
FAQ
Who is Steven K. Boyd and why was he appointed to the OraSure (OSUR) board on October 28, 2025?
When did Jack Kenny become Chair of the OraSure (OSUR) board and who did he succeed?
How has OraSure (OSUR) changed its board composition as of October 28, 2025?
Does the October 28, 2025 board update signal a strategic shift for OraSure (OSUR)?
What operational progress did OraSure (OSUR) cite alongside the board appointments on October 28, 2025?
